4 results
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
Primary:The primary objective is to determine the safety and tolerability of the combination treatment, i.e. GCb, VPA and GCV, by evaluation of adverse events (AE*s) serious adverse events (SAE*s) and all clinically significant changes in clinical…
The main objective of this study is to develop and investigate the (cost-) effectiveness of a pharmacist-led personalised intervention, with E-Health components, to analyse and improve medication adherence in people with T2DM, who are non-adherent…